Given the theoretical immunostimulatory aspect of IL-18 function, the paradox of finding increased circulating IL-18 as a negative prognostic portent has been discussed without resolution in the context of both pancreatic cancer [65] and breast cancer [66]. This evidence concerns the gene IL18 and breast cancer.